Race Oncology (ASX:RAC) received approval from the Bellberry Human Research Ethics Committee to start its RC220 Phase 1 clinical trial at Gosford and Wyong hospitals in New South Wales, according to a Monday filing with the Australian bourse.

The clinical research organization now expects to obtain final site approvals and activation by April, the filing said. Patient enrollment will start once these approvals are received. Human ethics approval for additional trial sites in Australia, Hong Kong, and South Korea is expected in the coming months.

The RAC-010 clinical trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 alone and in combination with doxorubicin in patients with solid tumors, the filing stated.